Furthermore, it has been reported that AMP-dNM treatment improves glucose tolerance, reduces hepatic steatosis, and enhances insulin response in rodent models of type 2 diabetes by downregulating GM3 [74,75], and reduces the development of atherosclerosis in model mice, in which the ganglioside contribution remains unknown [76]. This evidence concerns the gene INS and fatty liver disease.